In-practice Evaluation of Atacand 16mg Antihypertensive Effect

AstraZeneca

Status: Completed

Conditions: Essential Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT00802542

NIS-CLV-ATA-2008/1

Details and patient eligibility

About

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided
• Signed and dated Patient Informed Consent (ICF)

Exclusion criteria

• Hypersensitivity to the active substance or to any of the excipients of Atacand.

Trial design

400 participants in 1 patient group

1

Description:

Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.